{"entity":{"id":"nct05716087","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Rocbrutinib in mantle cell lymphoma, run by Guangzhou Lupeng Pharmaceutical Company LTD., active and no longer recruiting.","summary":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05716087 by Guangzhou Lupeng Pharmaceutical Company LTD., with 62 participants planned, started 2023-02-21 and due to reach its primary completion in 2024-12-05. Interventions recorded: Rocbrutinib. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05716087","url":"https://clinicaltrials.gov/study/NCT05716087"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rocbrutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05716087","phase":"2","setting":"An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","enrolled":62,"outcomes":[]},"route":"/trials/nct05716087/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/"}]}}